Artificial Intelligence in Cancer Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Application (Screening & Diagnosis, Tumor Identification, Surveillance, and Treatment), Cancer Type, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034
- Published Date:Apr-2025
- Pages: 125
- Format: PDF
- Report ID: PM2592
- Base Year: 2024
- Historical Data: 2020-2023
Artificial Intelligence in Cancer Diagnostics Market Overview
The artificial intelligence (AI) in cancer diagnostics market size was valued at USD 217.73 million in 2024. The market is projected to grow from USD 273.58 million in 2025 to USD 2,174.26 million by 2034, exhibiting a CAGR of 25.9% during 2025–2034.
The artificial intelligence in the cancer diagnostics market demand is rising due to the increasing adoption of AI-driven technologies in oncology. AI-powered diagnostic tools enhance early cancer detection, improve diagnostic accuracy, and reduce human error, contributing to better patient outcomes.
Key drivers of AI in the cancer diagnostics market growth include the rising prevalence of cancer, the growing demand for precision medicine, and advancements in machine learning and deep learning algorithms. Additionally, the integration of AI with medical imaging and pathology is streamlining cancer diagnosis. A few artificial intelligence in the cancer diagnostics market trends include the expansion of AI-based diagnostic solutions in emerging economies, regulatory advancements supporting AI adoption in healthcare, and increasing investments in AI-driven oncology research.
To Understand More About this Research: Request a Free Sample Report
Artificial Intelligence in Cancer Diagnostics Market Dynamics
Increasing Prevalence of Cancer
The rising incidence of cancer globally is a significant driver for the adoption of artificial intelligence in cancer diagnostics. According to the World Health Organization, approximately 20 million new cancer cases were reported in 2022, leading to 9.7 million deaths. This escalating burden necessitates advanced diagnostic tools to facilitate early detection and improve patient outcomes. AI technologies offer the potential to analyze complex medical data efficiently, aiding in the early detection of cancerous conditions, thereby propelling AI in cancer diagnostics market development.
Advancements in AI Algorithms and Imaging Technologies
Recent advancements in AI algorithms, particularly in machine learning and deep learning, have enhanced the accuracy and efficiency of cancer diagnostics. The integration of AI with advanced imaging technologies, such as MRI and CT scans, has improved the precision of cancer detection, which encourages the adoption of these advanced integrated devices. For instance, AI-powered platforms are being deployed to assist radiologists in interpreting scans, thereby accelerating diagnosis and reducing the workload on healthcare professionals. Hence, rising advancements in AI algorithms and imaging technologies are expected to offer artificial intelligence in the cancer diagnostics market opportunities during the forecast period.
Government Initiatives and Funding
Government support through funding and policy initiatives plays a crucial role in driving artificial intelligence in cancer diagnostics market expansion. The US government's Cancer Moonshot initiative aims to reduce cancer mortality by investing in AI data analysis to establish a nationwide ecosystem for data sharing among patients, doctors, and researchers. Such initiatives encourage the development and implementation of AI-driven diagnostic tools, fostering innovation in the cancer diagnostics.
-in-cancer-diagnostics-market-infographic.webp)
Artificial Intelligence in Cancer Diagnostics Market Segment Insights:
AI in Cancer Diagnostics Market Assessment by Application
The artificial intelligence in cancer diagnostics market, by application, is segmented into screening & diagnosis, tumor identification, surveillance, and treatment. The screening and diagnosis segment held the largest market share in 2024. This prominence is attributed to the integration of AI technologies in medical imaging and pathology, which enhances early cancer detection and diagnostic accuracy. AI algorithms assist in analyzing complex imaging data, facilitating the identification of malignancies at initial stages, thereby improving patient outcomes. The demand for AI-driven screening and diagnostic tools is further propelled by the increasing global cancer incidence and the need for efficient diagnostic solutions.
The tumor identification segment is experiencing the highest growth rate within this market. Advancements in machine learning and deep learning algorithms have significantly improved the precision of tumor detection and characterization. AI applications in tumor identification aid in distinguishing between benign and malignant tumors, assessing tumor boundaries, and evaluating metastatic spread. This rapid growth is driven by the continuous development of AI models capable of processing vast datasets to provide accurate tumor assessments, thereby supporting personalized treatment planning and monitoring.
Artificial Intelligence in Cancer Diagnostics Market Evaluation by Cancer Type
The artificial intelligence in cancer diagnostics market, by cancer type, is segmented into breast cancer, prostate cancer, lung cancer, colorectal cancer, cervical cancer, and others. The breast cancer segment dominated the market share in 2024. This is attributed to the high incidence of breast cancer globally, necessitating advanced diagnostic tools for early detection and treatment. AI technologies have been instrumental in enhancing the accuracy of mammography interpretations, leading to improved patient outcomes. According to the World Health Organization, approximately 2.3 million women were diagnosed with breast cancer in 2020, underscoring the critical need for effective diagnostic solutions.
The lung cancer segment is experiencing the highest growth rate within this market. This rapid expansion is driven by the increasing prevalence of lung cancer and the demand for precise diagnostic methods. AI applications in lung cancer diagnostics, such as the analysis of imaging data from CT scans, have shown promise in early detection and accurate tumor characterization. The integration of AI in these processes aids in identifying malignancies at earlier stages, thereby facilitating timely interventions and improving survival rates.
Artificial Intelligence in Cancer Diagnostics Market Outlook by End Use
The artificial intelligence in cancer diagnostics market, by end use, is segmented into hospitals, diagnostic centers, medical research institutes, contract research organizations, and others. The hospital segment holds the largest market share. This dominance is attributed to the widespread integration of AI algorithms into hospital workflows, addressing the shortage of healthcare professionals and enhancing the speed and accuracy of cancer diagnoses. Hospitals are increasingly adopting AI-powered diagnostic tools to improve patient outcomes and streamline operations. For instance, Addenbrooke’s Hospital in the UK implemented Microsoft's InnerEye, a deep-learning solution that significantly reduced CT processing time and treatment planning by 90%.
-in-cancer-diagnostics-market-segment.webp)
Artificial Intelligence in Cancer Diagnostics Market Regional Outlook
By region, the report provides AI in cancer diagnostics market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the largest market share in 2024. This dominance is attributed to the region's advanced healthcare infrastructure, significant investments in healthcare IT solutions, and the presence of key industry players. The increasing adoption of AI technologies in oncology, supported by substantial funding for AI development, further propels market growth in North America. Additionally, the rising prevalence of cancer and heightened patient awareness contribute to the expanding utilization of AI-driven diagnostic tools in the region.
The Europe AI in cancer diagnostics market is experiencing substantial growth, driven by significant investments and technological advancements. For instance, the European Investment Bank recently provided a €15 million loan to Spanish biotech company Amadix to develop innovative blood tests for early cancer detection. Additionally, institutions such as CERN are adapting AI models to revolutionize cancer treatment, collaborating with hospitals across Europe to enhance diagnostic accuracy and patient outcomes.
The Asia Pacific artificial intelligence in the cancer diagnostics market is rapidly expanding due to increasing healthcare investments and the adoption of AI technologies. Countries such as China and Japan are at the forefront of integrating AI into medical diagnostics to improve early cancer detection rates. The growing prevalence of cancer in the region, coupled with supportive government initiatives, is propelling the adoption of AI-driven diagnostic solutions. This trend is expected to continue, contributing significantly to advancements in cancer diagnostics and patient care.
-in-cancer-diagnostics-market-region.webp)
Artificial Intelligence in Cancer Diagnostics Market – Key Players and Competitive Analysis Report:
In the artificial intelligence in the cancer diagnostics market, several companies are actively contributing to advancements in early detection and treatment. Notable entities include Microsoft Corporation, IBM Corporation, Siemens Healthineers, GE Healthcare, and Tempus Labs, Inc. These organizations are at the forefront of integrating AI into healthcare to enhance diagnostic accuracy and patient outcomes.
Other significant contributors such as PathAI; Paige.AI, Inc.; and Kheiron Medical Technologies Limited specialize in developing AI-powered pathology solutions to improve cancer diagnosis. Additionally, companies such as Aidoc and Zebra Medical Vision are focusing on AI applications in medical imaging, aiding in the early detection of various cancers. Furthermore, Flatiron Health and Guardant Health are leveraging AI to analyze real-world oncology data and develop liquid biopsy technologies, respectively. These efforts collectively aim to revolutionize cancer diagnostics by providing more precise and less invasive testing options.
Microsoft Corporation and IBM Corporation are prominent entities in AI in the cancer diagnostics market. The company has been actively developing AI solutions to enhance cancer detection and treatment. In collaboration with Paige, a digital pathology provider, Microsoft is working on creating the world's largest image-based AI model for cancer detection. This model is being trained on up to four million digitized microscopy slides across various cancer types, utilizing Microsoft's advanced supercomputing infrastructure. The initiative aims to improve the accuracy and efficiency of cancer diagnosis, potentially leading to earlier detection and treatment for patients.
IBM Corporation has also made significant strides in applying AI to healthcare, particularly in oncology. IBM's Watson for Oncology and Watson for Genomics platforms assist physicians in providing personalized, evidence-based cancer care by analyzing vast amounts of medical data to identify tailored treatment options. These tools support clinical decision making by offering insights into various treatment possibilities based on extensive medical literature and patient data.
List of Key Companies in Artificial Intelligence in Cancer Diagnostics Market
- Aidoc Medical Ltd.
- DeepMind Technologies Limited
- Enlitic, Inc.
- Flatiron Health, Inc. (A subsidiary of Roche)
- GE Healthcare Technologies Inc.
- Guardant Health, Inc.
- IBM Corporation
- Kheiron Medical Technologies Limited
- Microsoft Corporation
- Paige.AI, Inc.
- PathAI, Inc.
- Qure.ai Technologies Private Limited
- Siemens Healthineers AG
- Tempus Labs, Inc.
- Zebra Medical Vision Ltd.
Artificial Intelligence in Cancer Diagnostics Industry Developments
- September 2024: PathAI, Inc. launched MET Predict on the AISight Image Management System (IMS). This AI-driven algorithm assists pathologists in detecting non-small cell lung cancer (NSCLC) tumors that may present MET exon 14 skipping (METex14) or MET amplification using H&E whole slide images.
- September 2023: Microsoft announced a partnership with Paige to develop the world's largest image-based AI model for cancer detection. The model is being trained on up to four million digitized microscopy slides across multiple cancer types, utilizing Microsoft's advanced supercomputing infrastructure. Once deployed, it is expected to enhance the accuracy and efficiency of cancer diagnosis, potentially leading to earlier detection and treatment for patients.
Artificial Intelligence in Cancer Diagnostics Market Segmentation
By Application Outlook (Revenue – USD Million, 2020–2034)
- Screening & Diagnosis
- Tumor Identification
- Surveillance
- Treatment
By Cancer Type Outlook (Revenue – USD Million, 2020–2034)
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Colorectal Cancer
- Cervical Cancer
- Others
By End Use Outlook (Revenue – USD Million, 2020–2034)
- Hospitals
- Diagnostic Centers
- Medical Research Institute
- Contract Research Organization
- Other
By Regional Outlook (Revenue – USD Million, 2020–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Artificial Intelligence (AI) in Cancer Diagnostics Market Report Scope
|
Report Attributes |
Details |
|
Market Size Value in 2024 |
USD 217.73 million |
|
Market Size Value in 2025 |
USD 273.58 million |
|
Revenue Forecast by 2034 |
USD 2,174.26 million |
|
CAGR |
25.9% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD million and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The market size was valued at USD 217.73 million in 2024 and is projected to grow to USD 2,174.26 million by 2034.
The market is projected to register a CAGR of 25.9% during the forecast period.
North America held the largest share of the market in 2024.
Several companies in the market are actively contributing to advancements in early detection and treatment. A few notable entities include Microsoft Corporation, IBM Corporation, Siemens Healthineers, GE Healthcare, and Tempus Labs, Inc. These organizations are at the forefront of integrating AI into healthcare to enhance diagnostic accuracy and patient outcomes.
The screening & diagnosis segment accounted for the largest share of the market in 2024.
Artificial intelligence in cancer diagnostics refers to the use of AI technologies, including machine learning, deep learning, and computer vision, to improve the accuracy, efficiency, and speed of cancer detection and diagnosis. AI-powered algorithms analyze medical imaging, pathology slides, and genomic data to identify cancerous cells, predict tumor progression, and assist healthcare professionals in making informed clinical decisions. These AI solutions help reduce diagnostic errors, enhance early detection, and personalize treatment plans by processing vast amounts of medical data. The integration of AI in cancer diagnostics aims to improve patient outcomes and streamline healthcare workflows.
A few key trends in the market are described below:
© 2025 Polaris Market Research and Consulting. All rights reserved
